Medical cannabis companies are the next big thing, right? Here's why you should steer clear.
Some stocks are so risky that valuing them becomes impossible. Here are three to avoid.
As John Cleese put it, ‘He who laughs most, learns best’.
Two companies dominate the betting industry and recent regulatory changes could make it a duopoly.
Cochlear demonstrated these six characteristics when we upgraded the stock to Buy in 2004. Look for them if you want to buy a wonderful business at a fair price.
BlueScope Steel’s stock has risen more than 900% since hitting bottom in July 2012. Here’s why I don’t care I missed it, and why you shouldn’t either.
The sudden demise of this former high-flyer is a stark reminder of the importance of understanding and managing risk.
Qantas points are already Australia's de facto second currency. Switching to blockchain would make it a real one.
All the world’s a stage, and last week Fletcher Building fell off. But the company’s problems are following a script and a buying opportunity mightn’t be far away.
A focus on the long term is never more important than when the markets get choppy.
Last week’s takeover for Sirtex Medical means our 2010 recommendation generated an annualised return of 24%. Read on for how to identify the next one.
Our updated annual list of the best online resources for value investors.